Mustang Bio is a clinical-stage biopharmaceutical company headquartered in Worcester, Massachusetts and founded in 2015. Their mission is to translate groundbreaking scientific discoveries in cell and gene therapy into potential cures for various diseases. Mustang Bio develops CAR T cell and lentiviral gene therapies to treat hematologic cancers like leukemia and lymphoma, solid tumors including glioblastoma, and X-linked severe combined immunodeficiency (X-SCID). Through partnerships with top medical institutions, Mustang Bio will be able to advance their development of CRISPR/Cas9 enhanced and classical CAR T therapies as well as lentiviral gene therapy.

Mustang Bio

Founded: 2015
Location: Worcester, MA
Employee range: 50 - 200
Clinical stage: Clin1
Therapy area: Newborn XSCID
Drug types: ONC, PED, GEN, IMM, RAR
Lead product: MB-107
Funding: 100-500M

Drug notes:

About:

Jobs: